Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $16.6 million.

  • Biodesix's Cash & Equivalents fell 4713.11% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 4713.11%. This contributed to the annual value of $26.2 million for FY2024, which is 14.84% down from last year.
  • According to the latest figures from Q3 2025, Biodesix's Cash & Equivalents is $16.6 million, which was down 4713.11% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Cash & Equivalents registered a high of $56.3 million during Q2 2021, and its lowest value of $11.5 million during Q1 2024.
  • Its 5-year average for Cash & Equivalents is $28.7 million, with a median of $25.3 million in 2023.
  • In the last 5 years, Biodesix's Cash & Equivalents surged by 65477.32% in 2021 and then plummeted by 7031.03% in 2022.
  • Quarter analysis of 5 years shows Biodesix's Cash & Equivalents stood at $32.7 million in 2021, then soared by 31.72% to $43.1 million in 2022, then tumbled by 39.0% to $26.3 million in 2023, then decreased by 0.15% to $26.2 million in 2024, then plummeted by 36.73% to $16.6 million in 2025.
  • Its Cash & Equivalents stands at $16.6 million for Q3 2025, versus $20.7 million for Q2 2025 and $17.6 million for Q1 2025.